Semaglutide does not increase cardiovascular events or mortality but causes more gastrointestinal side effects than placebo, according to meta-analysis of randomized trials.
No cardiovascular risk increaseAcross pooled randomized trial data, semaglutide did not increase cardiovascular events, sudden death, or overall mortality
What the researchers found
Semaglutide does not increase cardiovascular adverse events or mortality but is associated with higher rates of gastrointestinal side effects compared to placebo.
Why it matters
As semaglutide use expands rapidly for both diabetes and weight loss, having comprehensive safety data is critical for patients and doctors making treatment decisions.
The numbers in context
Primary outcome was cardiovascular adverse events. Secondary outcomes included sudden cardiac death, adverse events leading to death, and gastrointestinal side effects.
How the study worked
Meta-analysis of randomized controlled trials comparing semaglutide to placebo across various treatment durations and patient populations.
Who was studied
Patients with type 2 diabetes and/or obesity from randomized controlled trials
What this study cannot tell us
The analysis is limited to randomized trial data, which may not capture rare side effects. Real-world safety may differ from trial populations.
How to read the evidence
Rated strong: meta-analysis of randomized controlled trials provides the highest level of evidence for safety questions.
When this study was published
Published in 2024 as an updated meta-analysis reflecting the latest available trial data.
The bigger picture
With semaglutide's explosive growth for both diabetes and weight loss, comprehensive safety data is essential. This meta-analysis provides reassurance on cardiovascular safety while confirming the expected GI side effect profile.
Questions still open
- Are there rare side effects that even large trials might miss?
- Does the safety profile differ between diabetes and weight loss doses?
Common questions
Is semaglutide safe for the heart?
What are the most common side effects of semaglutide?
Read the original research
Evaluating the safety profile of semaglutide: an updated meta-analysis.
Current medical research and opinion, 40(9), 1495-1514
Citation
Rivera, Frederick Berro; Arias-Aguirre, Eloise; Aguirre, Zedrick; Ybañez, Mc John C; Rubia, Janos Marc M; Galang, Danica Janine; Lumbang, Grace Nooriza; Ruyeras, Jade Monica Marie J; Magalong, John Vincent; Pine, Polyn Luz; Amigo, John Andrew C; Ansay, Marie Francesca M; Zelenkov, Nenad; Thomas, Steve Samuel; Vijayaraghavan, Krishnaswami. (2024). Evaluating the safety profile of semaglutide: an updated meta-analysis.. Current medical research and opinion, 40(9), 1495-1514. https://doi.org/10.1080/03007995.2024.2383731